© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Ocaliva
First Large Study Shows Liver Fibrosis Improvement in People with NASH
food with high fiber content for a healthy diet with fruit, vegetables, whole wheat bread, pasta, nuts, legumes, grains and cereals
How Is NAFLD/NASH Treated Today?
NAFLD/NASH Medication Pipeline

Company Halts Leading NASH Drug but Another Shows Promise

Studies of PPAR agonists have yielded mixed results for people with fatty liver disease.

Ocaliva Improves Liver Fibrosis in People With NASH

About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.

Intercept Seeks Approval of Ocaliva for NASH

The application is based on study results showing that up to 23% of treated patients saw an improvement in liver fibrosis.

Intercept’s NASH Drug

A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis.

International Liver Congress Roundup

A quick overview of our reporting on the 53rd International Liver Congress in Vienna

What Is Primary Biliary Cholangitis?

Generic image

NAFLD/NASH Medications

The NAFLD/NASH medications’ page includes specific information about each of the experimental dru...

Ocaliva

FDA Approves Ocaliva, New Drug for Primary Biliary Cholangitis (PBC)

The FDA has approved Intercept Pharmaceuticals’ Ocaliva to treat primary biliary cholangitis, previously known as primary biliary cirrhosis.

Intercept NASH Drug OCA Gets FDA Fast-Track Status

The drug has been shown to help reduce markers of liver inflammation and fibrosis, as well as increase insulin sensitivity.
Advertisement